SCYX Scynexis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SCYX

Price (delayed)

$3.82

Market cap

$37.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.84

Enterprise value

$11.13M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 35

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly ...

Highlights
The company's net income has shrunk by 185% QoQ but it rose by 9% YoY
The company's EPS has shrunk by 182% QoQ but it rose by 14% YoY
Scynexis's quick ratio has decreased by 47% QoQ and by 34% YoY
The equity has declined by 18% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.scynexis.com
Peers: CPRX

Key stats

What are the main financial stats of SCYX

SCYX stock price

How has the Scynexis stock price performed over time
Intraday
0.53%
1 week
-6.6%
1 month
-34.7%
1 year
-34.59%
YTD
-24.51%
QTD
-47.96%

Financial performance

How have Scynexis's revenue and profit performed over time
Revenue
$20.34M
Gross profit
$20.34M
Operating income
-$24.38M
Net income
-$24.52M
Gross margin
100%
Net margin
-120.5%
Scynexis's net margin has plunged by 188% from the previous quarter but it has soared by 88% YoY
The company's net income has shrunk by 185% QoQ but it rose by 9% YoY
The operating margin has soared by 91% YoY but it has plunged by 54% from the previous quarter
SCYX's operating income has shrunk by 52% QoQ but it is up by 33% YoY

Price vs fundamentals

How does SCYX's price correlate with its fundamentals

Growth

What is Scynexis's growth rate over time

Valuation

What is Scynexis stock price valuation
P/E
N/A
P/B
0.52
P/S
1.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.55
The company's EPS has shrunk by 182% QoQ but it rose by 14% YoY
SCYX's price to book (P/B) is 79% lower than its 5-year quarterly average of 2.5 and 35% lower than its last 4 quarters average of 0.8
The equity has declined by 18% year-on-year and by 16% since the previous quarter
The P/S is 92% lower than the 5-year quarterly average of 14.2 and 82% lower than the last 4 quarters average of 6.8

Efficiency

How efficient is Scynexis business performance
The company's return on sales has shrunk by 195% QoQ but it has surged by 88% YoY
Scynexis's return on assets has shrunk by 174% QoQ and by 33% YoY
SCYX's return on invested capital has dropped by 65% year-on-year
The return on equity has declined by 18% year-on-year

Dividends

What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SCYX.

Financial health

How did Scynexis financials performed over time
The total assets is 114% more than the total liabilities
The total liabilities has soared by 109% YoY
Scynexis's quick ratio has decreased by 47% QoQ and by 34% YoY
Scynexis's debt is 76% less than its equity
The equity has declined by 18% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.